Tumor Characteristics
 FHCRC-07-16-2013-009.jpg
GECCO extended its investigation to include tumor marker data, as a subset of studies has already conducted tumor marker testing (including BRAF, KRAS, CIMP, IHC, MSI, and MMR). Additionally, several studies have tumor tissue samples available for targeted sequencing.

Grant Aims

‚Äč1. Harmonize existing molecular tumor characteristics (BRAF, KRAS, MSI, and CIMP).

2. Generate a comprehensive profile of somatic tumor DNA mutations through targeted, deep sequencing. Using this mutational profile, we will define CRC subtypes based on mutated pathways.

For each aim, we will investigate associations between tumor subtypes and:

a. Common and rare germline genetic variants across the genome, including the use of functionally informed set-based tests to improve statistical power for evaluating rare variants.

b. Lifestyle, environmental, and familial risk factors, including alcohol, smoking, obesity, physical activity, use of non-steroidal anti-inflammatory drugs (NSAIDs), exogenous hormone use, dietary factors (red meat, processed meat, fruit, vegetables, fiber, folate, and calcium), and family history lcohol, smoking, obesity, physical activity, use of non-steroidal anti-inflammatory drugs (NSAIDs), exogenous hormone use, dietary factors (red meat, processed meat, fruit, vegetables, fiber, folate, and calcium), and family history of CRC.


Additionally, we received supplemental funding to do targeted sequencing on ~250 metastatic samples.